https://www.cmacuk.org/a-joint-statement-on-the-voluntary-scheme-for-branded-medicines-pricing-and-access-vpas/2025-06-26T09:00:16+00:00https://www.cmacuk.org/our-open-letter-to-government-about-the-abpi/2025-06-26T08:54:41+00:00https://www.cmacuk.org/joint-statement-on-the-commercial-framework-consultation/2025-06-26T09:18:04+00:00https://www.cmacuk.org/response-to-consulation-about-the-inclusion-of-technology-appraisal-recommendations-in-nice-guidelines/2025-06-26T08:56:09+00:00https://www.cmacuk.org/response-to-consulation-about-nices-integrated-topic-prioritisation-and-strategic-principles/2025-07-02T14:21:48+00:00https://www.cmacuk.org/response-to-the-commercial-framework-consulation-part-1/2025-07-04T14:56:08+00:00https://www.cmacuk.org/response-to-nices-consultation-on-the-criteria-for-highly-specialised-technologies/2025-07-09T10:04:48+00:00https://www.cmacuk.org/statement-on-voluntary-scheme-for-branded-medicines-pricing-and-access-vpag-accelerated-review/2025-07-02T14:34:37+00:00https://www.cmacuk.org/cmac-statement-uk-us-trade-deal/2026-06-09T16:32:10+00:00https://www.cmacuk.org/statement-about-department-of-health-social-care-dhsc-consultation-changes-to-nice-regulations-cost-effectiveness-threshold/2026-02-06T09:45:28+00:00https://www.cmacuk.org/cmac-and-mhp-group-host-a-series-of-webinars-about-access-to-medicines/2026-07-14T20:00:04+00:00